Sodium Zirconium Cyclosilicate Lowers Hyperkalemia After Parathyroidectomy

Summary

Sodium zirconium cyclosilicate (SZC) has been demonstrated for its serum potassium-lowering efficacy and safety in hyperkalemia hemodialysis patients. However, the effects of SZC during the perioperative period remained unknown. This experiment aimed to determine whether using SZC would impact the serum potassium levels in patients with maintenance hemodialysis after parathyroidectomy (PTX).

Timeline

Start

2016-11

Primary completion

2021-12

Completion

2021-12

Publications

• Kang J, Li S, Su J, Xiao Z, Zhang S, Liu S, Ge P. Effect of sodium zirconium cyclosilicate on hyperkalemia after parathyroidectomy in secondary hyperparathyroidism patients with maintenance hemodialysis: A randomized trial. Medicine (Baltimore). 2024 Dec 27;103(52):e40917. doi: 10.1097/MD.0000000000040917.

Drugs

Indications